scispace - formally typeset
Open AccessJournal ArticleDOI

A Systematic Review on the Efficacy and Safety of Chloroquine for the Treatment of COVID-19

Andrea Cortegiani, +4 more
- 10 Mar 2020 - 
- Vol. 57, pp 279-283
TLDR
There is rationale, pre-clinical evidence of effectiveness and evidence of safety from long-time clinical use for other indications to justify clinical research on chloroquine in patients with COVID-19.
About: 
This article is published in Journal of Critical Care.The article was published on 2020-03-10 and is currently open access. It has received 870 citations till now. The article focuses on the topics: Clinical trial & Clinical research.

read more

Citations
More filters
Journal ArticleDOI

Revisión narrativa sobre la respuesta inmunitaria frente a coronavirus: descripción general, aplicabilidad para SARS-COV-2 e implicaciones terapéuticas

Alberto García-Salido
- 01 Jul 2020 - 
TL;DR: The nuevo coronavirus (SARS-CoV-2) productor de sindrome respiratorio agudo severo surge en Wuhan, China, en diciembre de 2019 as discussed by the authors.
Journal ArticleDOI

An Umbrella Review of Clinical Efficacy and Adverse Cardiac Events Associated with Hydroxychloroquine or Chloroquine with or Without Azithromycin in Patients with COVID-19.

Kavous Shahsavarinia, +5 more
- 15 Aug 2021 - 
TL;DR: No benefit was found for patients with COVID-19 who received hydroxychloroquine or chloroquine alone or in combination with azithromycin and it is noteworthy that these medications, particularly when considering co-administration, could result in both statistically and clinically elevated risks of notorious arrhythmias, such as TdP.
Journal ArticleDOI

Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?

Lauren A Schluenz, +2 more
- 01 Sep 2020 - 
TL;DR: The United States Food and Drug Administration has declared that the potential benefits of these agents no longer outweigh the possible risks, and unless new emerging information suggests a more favorable risk:benefit ratio, neither chloroquine nor hydroxychloroquine should be recommended for COVID-19 treatment or prevention at this time.
Journal ArticleDOI

The current recommended drugs and strategies for the treatment of coronavirus disease (COVID-19)

Mojgan Sheikhpour
- 07 Oct 2020 - 
TL;DR: Fluoxetine, as a host-targeted small molecule with immunomodulatory action, may be known as effective drug for treatment and prevention of COVID19 disease, in combination with antiviral drugs and natural compounds.
Journal ArticleDOI

Micro/nano biomedical devices for point-of-care diagnosis of infectious respiratory diseases

Yang Wang, +6 more
- 01 Feb 2022 - 
TL;DR: In this article , the authors provide a comprehensive overview of the latest advances on the POCT device for diagnosis of COVID-19, which may provide insightful knowledge for researcher to further develop novel diagnostic technologies for rapid and on-site detection of pathogens including SARS-CoV-2.
References
More filters
Journal ArticleDOI

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang, +28 more
- 24 Jan 2020 - 
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported.
Journal ArticleDOI

Clinical Characteristics of Coronavirus Disease 2019 in China.

Wei-jie Guan, +36 more
- 28 Feb 2020 - 
TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.
Journal ArticleDOI

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Dawei Wang, +13 more
- 17 Mar 2020 - 
TL;DR: The epidemiological and clinical characteristics of novel coronavirus (2019-nCoV)-infected pneumonia in Wuhan, China, and hospital-associated transmission as the presumed mechanism of infection for affected health professionals and hospitalized patients are described.
Journal ArticleDOI

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu, +1 more
- 07 Apr 2020 - 
TL;DR: Hospitalised COVID-19 patients are frequently elderly subjects with co-morbidities receiving polypharmacy, all of which are known risk factors for d
Journal ArticleDOI

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.

Xiaobo Yang, +17 more
- 01 May 2020 - 
TL;DR: The clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital between late December, 2019 and Jan 26, 2020 are described.
Related Papers (5)

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang, +28 more
- 24 Jan 2020 - 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Nanshan Chen, +13 more
- 30 Jan 2020 - 

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann, +13 more
- 16 Apr 2020 - 

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Fei Zhou, +19 more
- 28 Mar 2020 - 

Clinical Characteristics of Coronavirus Disease 2019 in China.

Wei-jie Guan, +36 more
- 28 Feb 2020 -